IOL Chemicals & Pharmaceuticals Ltd
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]
It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]
- Market Cap ₹ 1,902 Cr.
- Current Price ₹ 64.8
- High / Low ₹ 108 / 57.5
- Stock P/E 19.6
- Book Value ₹ 56.5
- Dividend Yield 1.54 %
- ROCE 12.2 %
- ROE 8.61 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Stock is trading at 1.15 times its book value
- Company has been maintaining a healthy dividend payout of 17.6%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE SmallCap BSE Healthcare BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|
2,184 | 2,217 | 2,133 | 2,055 | |
1,925 | 1,991 | 1,902 | 1,866 | |
Operating Profit | 259 | 226 | 231 | 189 |
OPM % | 12% | 10% | 11% | 9% |
17 | 25 | 30 | 25 | |
Interest | 8 | 16 | 16 | 14 |
Depreciation | 43 | 46 | 63 | 70 |
Profit before tax | 225 | 189 | 182 | 130 |
Tax % | 25% | 26% | 26% | |
168 | 139 | 134 | 97 | |
EPS in Rs | 5.71 | 4.74 | 4.58 | 3.31 |
Dividend Payout % | 14% | 17% | 22% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -7% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -43% |
Stock Price CAGR | |
---|---|
10 Years: | 20% |
5 Years: | 2% |
3 Years: | -10% |
1 Year: | -18% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|
Equity Capital | 59 | 59 | 59 | 59 |
Reserves | 1,334 | 1,449 | 1,553 | 1,601 |
44 | 80 | 33 | 128 | |
526 | 435 | 600 | 477 | |
Total Liabilities | 1,962 | 2,022 | 2,244 | 2,265 |
561 | 752 | 933 | 1,012 | |
CWIP | 105 | 90 | 101 | 122 |
Investments | 2 | 20 | 20 | 21 |
1,294 | 1,161 | 1,190 | 1,111 | |
Total Assets | 1,962 | 2,022 | 2,244 | 2,265 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
93 | 122 | 290 | |
-121 | -120 | -191 | |
-2 | -4 | -92 | |
Net Cash Flow | -29 | -2 | 6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|
Debtor Days | 79 | 83 | 81 |
Inventory Days | 95 | 77 | 111 |
Days Payable | 95 | 74 | 123 |
Cash Conversion Cycle | 79 | 86 | 69 |
Working Capital Days | 78 | 86 | 76 |
ROCE % | 14% | 12% |
Documents
Announcements
-
Intimation Under SEBI (LODR) Regulations, 2015 - CDE, China Approved 'Ibuprofen'
2d - Ibuprofen approved by China's CDE for export, enabling market entry in China.
-
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
2d - Minor gas leak at Punjab plant caused one death, three injuries; operations unaffected.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 4 Apr
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 3 Apr
-
Closure of Trading Window
26 Mar - Closure of trading window from April 1, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Mar 2021Transcript PPT
-
Dec 2020Transcript PPT
-
Nov 2020TranscriptNotesPPT
Business Segments